CoChat

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Open access
Loddick, Sarah A., Ross, Sarah J., Thomason, Andrew G., Robinson, David M., Walker, Graeme E., Dunkley, Tom P.J., Brave, Sandra R., Broadbent, Nicola, Stratton, Natalie C., Trueman, Dawn, Mouchet, Elizabeth, Shaheen, Fadhel S., Jacobs, Vivien N., Cumberbatch, Marie, Wilson, Joanne, Jones, Rhys D.O., Bradbury, Robert H., Rabow, Alfred, Gaughan, Luke, Womack, Chris, Barry, Simon T., Robson, Craig N., Critchlow, Susan E., Wedge, Stephen R., Brooks, A. Nigel · 2013 · Molecular Cancer Therapeutics
Cited by 79

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC) after classical androgen ablation therapies have failed, and therefore remains a target for the treatment of progressive disease. Here, we describe the biological characterization of AZD3514, an orally bioavailable drug that inhibits androgen-dependent and -independent AR signaling. AZD3514 modulates AR signaling through two distinct mechanisms, an inhibition of ligand-driven nuclear translocation of AR and a downregulation of receptor levels, both of which were observed in vitro and in vivo. AZD3514 inhibited testosterone-driven seminal vesicle development in juvenile male rats and the growth of androgen-dependent Dunning R3327H prostate tumors in adult rats. Furthermore, this class of compound showed antitumor activity in the HID28 mouse model of CRPC in vivo. AZD3514 is currently in phase I clinical evaluation. Mol Cancer Ther; 12(9); 1715–27. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-12-1174

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 79

Metadata

Authors
Loddick, S. A., Ross, S. J., Thomason, A. G., Robinson, D. M., Walker, G. E., Dunkley, T. P. J., Brave, S. R., Broadbent, N., Stratton, N. C., Trueman, D., Mouchet, E., Shaheen, F. S., Jacobs, V. N., Cumberbatch, M., Wilson, J., Jones, R. D. O., Bradbury, R. H., Rabow, A., Gaughan, L., Womack, C., Barry, S. T., Robson, C. N., Critchlow, S. E., Wedge, S. R., & Brooks, A. N.
Venue
Molecular Cancer Therapeutics
Published
2013-09-01
Volume
12
Issue
9
Pages
1715-1727
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2126959871
Cited by
79
References
11
FWCI
7.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-1174
The paper
Loddick, S. A., Ross, S. J., Thomason, A. G., Robinson, D. M., Walker, G. E., Dunkley, T. P. J., Brave, S. R., Broadbent, N., Stratton, N. C., Trueman, D., Mouchet, E., Shaheen, F. S., Jacobs, V. N., Cumberbatch, M., Wilson, J., Jones, R. D. O., Bradbury, R. H., Rabow, A., Gaughan, L., . . . Brooks, A. N. (2013). AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-1174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.